This study is for people with advanced lung cancer, specifically non-small cell lung cancer (NSCLC), who have already had treatments like platinum chemotherapy and immunotherapy. The study is about adding a medicine called cemiplimab to usual treatments, docetaxel and ramucirumab. Cemiplimab is a type of drug called a monoclonal antibody that helps the immune system fight cancer by blocking a pathway called PD-1. Docetaxel and ramucirumab are other drugs used to stop cancer cells from growing. The study wants to see if adding cemiplimab helps people live longer and if it works better than just using docetaxel and ramucirumab alone. Participants in the study will be randomly assigned to two different groups, with one group receiving cemiplimab in addition to the usual treatment, while the other group will receive the usual treatment alone. The study involves regular visits for treatment and tests like blood samples and scans.

• The study lasts for several weeks, with follow-ups every 3-6 months for up to 3 years.
• Participants may need to visit the hospital for treatments and tests every 21 days.
• Participants will receive compensation for their involvement and contribution to the study.